Skip to main content

Week In Review: Six China Biopharma Deals Raise A Total Of $255 Million

Immvira Group, a Shenzhen biotech developing oncolytic virus therapies, completed a $58 million Series B financing. Miaoshou Doctor, an online-offline healthcare company headquartered in Beijing, closed an $85 million Series D1 round.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.